Premium
Primary Treatment of Ranula With Intracystic Injection of OK‐432
Author(s) -
Roh JongLyel
Publication year - 2006
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/01.mlg.0000191458.23867.88
Subject(s) - ranula , medicine , sclerotherapy , surgery
Objective: Although surgery is the first choice of therapy for ranula, it was made a hypothesis that ranula can be primarily treated with sclerotherapy from prior evidence. This study examined the effectiveness of intracystic injection of OK‐432 for treatment of ranula. Method: This prospective clinical study comprised a total of 26 patients with ranula (19 intraoral type; seven plunging type) treated with OK‐432 sclerotherapy. Aspirated mucus of ranula was replaced with an equal volume of OK‐432 solution of 0.01 mg/mL. The size of ranula was compared before and after sclerotherapy. Results: Twenty of 26 patients (77%) showed a complete response after sclerotherapy: higher in plunging ranula (86%) than in intraoral ranula (74%). Rupture of ranula developed in seven of 19 patients (37%) with intraoral ranula within a few days after injection. The early rupture occurred more frequently in patients having a less‐than‐marked response and seemed to cause an increase in the total number of OK‐432 injections: seven ruptured cases versus 12 nonruptured cases (mean 3.6 versus 1.5, P < .001). Recurrence occurred in two patients during a median follow‐up period of 12 months (range, 9–22 mo) after the last injection. There were no major side effects, scarring, or increased morbidity to surgery of the OK‐432‐injected lesions. Conclusion: The intracystic injection of OK‐432 is highly effective as a primary treatment modality of ranula.